SUPPLEMENTAL APPENDIX

Similar documents
Abstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ

BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib

Abstract #163 Michael Kalos, PhD

Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA

FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated

Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH

Is in vitro T-cell depletion necessary for Haploidentical TransplantationTitle of Presentation. Disclosure of Interest: Nothing to Disclose

Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain

M Y ELO I D D I FFER ENTIATI O N OPENS UP THE POSSIBILITIES

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities

NY-ESO SPEAR T-cells in Synovial Sarcoma

BESPONSA (inotuzumab ozogamicin)

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives:

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)

Nilotinib AEs (adverse events) in CML population:

Stem Cell Transplantation and Cellular Therapy, MDACC, Houston, TX. Intrexon, Germantown, MD. Pediatrics, MDACC. Ziopharm Oncology, Boston, MA

Myeloma Support Group: Now and the Horizon. Brian McClune, DO

First relapsed childhood ALL Role of chemotherapy

Product: Blinatumomab Clinical Study Report: MT Date: 11 July 2014 Page 1

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities

Online Supplementary Data. Country Number of centers Number of patients randomized

The question is not whether or not to deplete T-cells, but how to deplete which T-cells

ASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS

Leukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington

CAR T CELL IMMUNOTHERAPY FOR ALL. Stephan Grupp, MD, PhD

screening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib

ETP - Acute Lymphoblastic Leukaemia

Objectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future

MS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

The Role of Conventional Donor Lymphocyte Transfusions. Hans-Jochem Kolb 3rd Med. Dept. Klinikum re der Isar Technische Universitaet Muenchen Germany

Background CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.

Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).

Management of Acute Lymphoblastic Leukemia

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy

Personalized medicine - cancer immunotherapy

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

(212) (347)

ELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with low to intermediate risk (WBC less than 10 x 10 9 /L)

SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)

TKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients. Moustafa Sameer Hematology Medical Advsior,Novartis oncology

BR is an established treatment regimen for CLL in the front-line and R/R settings

Ohio State University, Columbus, OH.

Reuben BENJAMIN, MD, PhD, Principal Investigator

CAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center

Supplementary Appendix

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

Study No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

Phase I Trial of Siplizumab in CD-2 Positive Lymphoproliferative Disease

CML TREATMENT GUIDELINES

CARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center

Pharmacy Prior Authorization

Cytokine Release Syndrome and Neurotoxicity

Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

BiTE in ALL and AML. Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes. Shannon L.

The BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine

Supplementary Online Content

2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

Tasigna. Tasigna (nilotinib) Description

Previous Study Return to List Next Study

EHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication)

Tasigna. Tasigna (nilotinib) Description

A PHASE I STUDY OF INTRAVENOUS RECOMBINANT HUMAN IL-15 (rhil-15) IN ADULTS WITH METASTATIC MALIGNANT MELANOMA AND METASTATIC RENAL CELL CANCER

Subject ID: I N D # # U A * Consent Date: Day Month Year

Applying Chimeric Antigen Receptor T cells (CAR-T) to hematologic malignancies

ACUTE LYMPHOBLASTIC LEUKEMIA

Update to the Human Leukocyte Antigens (HLA) Equivalency Tables

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Pediatric Oncology. Vlad Radulescu, MD

Severe Neurotoxicity in the Phase 2 Trial of JCAR015 in Adult B-ALL (ROCKET Study): Analysis of Patient, Protocol and Product Attributes

ULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician

IDH1 AND IDH2 MUTATIONS

Sponsor / Company: Sanofi Drug substance(s): SAR (iniparib)

ELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with high risk (WBC more than 10 x 10 9 /L)

Immunotherapies in Acute Lymphoblastic Leukaemia. Professor David Ritchie Royal Melbourne Hospital

Cautionary Note Regarding Forward-Looking Statements

HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS

Targeting CD123 in Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs )

Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL

COG-ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Minor H Antigen-Specific T Cells -The Black Box of the GVL Effect

J Clin Oncol 36: by American Society of Clinical Oncology INTRODUCTION

Update: Chronic Lymphocytic Leukemia

CLINICAL STUDY REPORT SYNOPSIS

Supplementary Appendix

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES ALDO E CELE DACCO

Acute Myeloid Leukemia

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES

Update: New Treatment Modalities

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

April 7, Introduction

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)

Transcription:

SUPPLEMENTAL APPENDIX Table of Contents 1. Supplemental Tables 2. Supplemental Figures Nature Medicine: doi:1.138/nm.4441

Supplemental Table 1. Baseline Characteristics of Patients Treated with anti-cd22 CAR T cells Demographic Status Prior Therapy s CD19 Immunotherapy CD22 Antibody Circulating B Marrow Blast Blast CD22 Pt Age Extramedullary Sex HSCT cells/mcl Blasts CD19 Site Density # (yrs) Agent Response Agent Response disease (non-malignant) (%)* Expression (number/cell) 1 22 M Y CD19.BB.z-CAR CR Ino SD 5 99.** --- Neg 2,84 2 2 F Y (2) CD19.28.z-CAR CR --- --- 623 5.^ --- Dim 13,452 3 22 M Y CD19.BB.z-CAR CR --- --- 2 97. --- Neg 846 4 22 M Y CD19.28.z-CAR PD --- --- 3 99. --- Pos 1,867 5 7 F Y CD19.BB.z-CAR CR --- --- 78. --- Neg 2,839 6 17 F Y CD19.BB.z-CAR CR --- --- 2.6 --- Neg 4,988 7 17 M Y (2) --- --- --- --- 121 2.6 --- Pos 8,514 8 19 F Y --- --- --- --- 9.3 --- Pos 1,432 9 21 F Y CD19.BB.z-CAR CR --- --- 91. --- Neg 1,866 1 26 M Y Blinatumomab PD --- --- 48 >99. --- Pos 8,43 11 7 M Y CD19.28.z-CAR @^ PD Ino CR 391 19. --- Pos 4,816 12 15 M Y CD19.28.z-CAR CR Ino CR 17.5 Renal mass, Vertebral body masses Pos 922 13 3 M Y CD19.28.z-CAR CR --- --- 27. Renal mass, Vertebral body masses, abdominal lymphadenopathy Neg 3,575 14 18 F Y --- --- --- --- 488 3. --- Pos 7,722 15 8 F Y CD19.BB.z-CAR CR Ino CR 94. Temporal mass Neg 99 16 26 M Y Blinatumomab CR --- --- 131 77. --- Neg 4,568 17 27 M Y CD19.28.z-CAR @ CR Ino CR 1 17. Pleural Effusion Pos 613 # 18 12 M N --- --- --- --- 26 75. --- Pos 2,267 19 19 M Y CD19.BB.z-CAR CR --- --- 87. --- Neg 2,196 2 8 F Y CD19.BB.z-CAR CR --- --- 455 7.5 --- Pos 5,779 21 12 M N CD19.28.z-CAR CR --- --- 111 2.6 --- Pos 9,197 M=male; F=female; HSCT=allogeneic hematopoietic stem cell transplantation; Y=yes; N=no; CR=complete remission; PD=progressive disease; Ino=Inotuzumab; all CRs were MRD negative * % blasts of mononuclear cells by flow cytometry, except when indicated otherwise. ** marrow biopsy, as patient was unaspirable. ^% blasts in peripheral blood that developed following enrollment marrow, prior to therapy. # Partial CD22 expression at baseline (post-cd22 targeted antibody therapy). @ Also received prior blinatumomab. ^Non-responder to CD19 CAR and blinatumomab. Nature Medicine: doi:1.138/nm.4441

Supplemental Table 2. Characteristics of Infused anti-cd22 CAR-T Cell Product Pt. # Cell Dose (1 6 /kg) % Transduced (Protein L) %CD3 % CD4 %CD8 Cryopreserved Prior to Infusion? 1.3.2% 98.8% 13.4% 84.9% N 2.3.1% 99.9% 63.6% 35.4% Y 3.3 41.2% 98.1% 33.1% 63.8% N 4.3 45.% 99.6% 94.3% 5.% Y 5.3 31.7% 99.8% 42.8% 56.9% Y 6.3 34.7% 99.3% 36.3% 44.% Y 7 1 47.8% 99.8% 7.9% 26.8% N 8 1 23.4% 99.2%.8% 72.7% Y 9 1 36.9% 99.8% 67.6% 3.8% Y 1 3 33.4% 96.8% 67% 28.6% Y 11 3 18.8% 99.9% 78.6% 17.2% N 12 1 28.8% 99.8% 49%.% N 13 1 18% 99.6% 75.55 23.6% N 14 1 4.7% 99.8% 76.8% 22.3% N 15 1 15.4% 99.5% 6.5% 38% N 16 1 23.1% 99.6% 51.1% 48.1% Y 17 1 28.5% 99.7% 56.9% 41.8% N 18 1 39.1% 99.9% 69.4% 29.3% Y 19 1 29.2% 99.9% 46.3% 51% N 2 1 48.7% 99.8% 59.8% 38.1% N 21 1 33.4% 99.7% 32.5% 66.1% N Nature Medicine: doi:1.138/nm.4441

Supplemental Table 3. Grade 3 and 4 Adverse Events at Least Possibly Related to CD22 CAR T cells from Time of Infusion through Day 28 Dose 1 Dose 2 Dose 3 3 4 3 4 3 4 Blood & Lymphatic System Disorders Anemia 1 1 Febrile neutropenia 6 14 2 Cardiac Disorders Sinus tachycardia 1 Gastrointestinal Disorders Diarrhea 1 1 General disorders and administration site conditions Fever 2 1 11 2 Multi-organ failure 1 Infections and Infestations Catheter related infections 1 Sepsis 1 Investigations Activated partial thromboplastin time prolonged 3 Alanine aminotransferase increased 1 Alkaline phosphatase increased 2 Aspartate aminotransferase increased 1 6 1 1 Blood bilirubin increased 2 CPK increased 1 Fibrinogen decreased 4 GGT increased 1 INR increased 1 Lipase increased 1 1 Lymphocyte count decreased 13 7 3 1 Neutrophil count decreased 4 6 15 11 4 2 Platelet count decreased 3 2 22 17 8 7 Serum amylase increased 1 Urine output decreased 1 Weight gain 1 White blood cell decreased 6 2 14 11 6 5 Metabolism and nutrition disorders Hypertriglyceridemia 6 2 Hypokalemia 3 4 Hyponatremia 7 1 Hypophosphatemia 2 1 26 1 4 Tumor lysis syndrome 1 Respiratory, thoracic and mediastinal disorders Epistaxis 1 Hypoxia 2 1 Respiratory failure 1 Vascular disorders Hypotension 1 3 1 Nature Medicine: doi:1.138/nm.4441

Supplemental Table 4. CAR-T Cell Expansion, Leukemia Response and Toxicity CAR T Cell Dose (1 6 cells/kg) Pt # Maximum Circulating CAR/µl CAR T Cell Expansion Toxicity Response Maximum $ Marrow CSF $ Pleural Circulating Fluis $ CRS DLT Maximum Response CAR % # (%) (%) Grade (Grade) Response Duration (%) 1 2 1.1 n/a --- None No PD n/a 2 316 52.3 19.5 &. --- 1 Yes (3) CR 3 mos.3 3 44 73. 36. 32. --- 1 No SD n/a 4 1 6.. --- 2 No SD n/a 5. 1.3. --- None No PD n/a 6 9 1.8 2.. --- None No PD n/a 7 424 62. 24. 52. --- 2 No CR + 21 mos+ 1 8 481 36.2 6. 26. --- 1 No CR 6 mos 9 1217 75. 28. 6.* --- 2 No CR 6 mos 3 1 15 14.3 n/a --- 2 Yes (4) SD n/s 11 732 72 27.6 & 21 --- 1 No CR 1.5 mos 12 4 2.6 --- None No SD n/a 13 15 6 42 69 --- 1 No CR ** 12 mos 14 1 62 n/a n/a --- 2 Yes (5) CR n/a 15 3593 77 41 61 --- 1 No CR 2 mos 1 16 762 64 4 27 --- 1 No CR + 9 mos+ 17 2167 89.5 78.2 71.6 73 2 Yes (4) SD n/a 18 n/a n/a --- None No PD n/a 19 2184 91 71 45 --- 2 No CR 6 mos 2 2831 8 57 --- 1 No CR 6 mos 21 324 76 31 41 --- 1 No CR + 6 mos+ # % of CD3 cells co-expressing CD22-CAR; $ % of T cells on Day 28±4; & BM obtained at 6 weeks; *CSF obtained at 2 mos; CRS=Cytokine Release Syndrome; DLT=dose limiting toxicity; PD=Progressive Disease; CR=complete response; SD=stable disease; PD=progressive disease MRD negative bone marrow, **Attained MRD negative remission in the marrow on Day 28 with decreasing PET-avidity seen in the lymphomatous components of the disease that fully resolved by 5 months post-car therapy. +Response ongoing, death due to sepsis Nature Medicine: doi:1.138/nm.4441

Supplemental Figure 1: Serum cytokine profiles following CD22 CAR T cells demonstrate multiple distinct patterns. Serial cytokines were prospectively measured on all patients and representative profiles are shown here. Patients #2, 7, and 9 were all responders and experienced cytokine release syndrome. Of note, patient 7 had low burden leukemia at time of treatment, patient #2 had intermediate leukemic burden and patient #9 had high leukemic burden. Patient #4 had high leukemic burden prior to CD22 CAR treatment, demonstrated cytokine release syndrome with elevations of cytokines as illustrated, and experienced a transient reduction in leukemic blasts following CD22-CAR therapy but did not attain remission. 16 14 12 1 8 6 4 2 Pt##2 1 3 5 7 9 11 13 15 17 19 21 28 12 1 8 6 4 2 Pt##4 1 3 5 7 9 11 13 15 17 19 21 28 2 175 1 1 1 75 Pt##7 1 3 5 7 9 11 13 15 17 19 21 28 13 1 7 4 1 Pt##9 1 3 5 7 9 11 13 15 17 19 21 28 Nature Medicine: doi:1.138/nm.4441

Supplemental Figure 2: Serum cytokine profiles following CD22 CAR T cells demonstrate multiple distinct patterns. Patients #8, 11, 13, 14, 15 and 16 all attained complete remission. 6 4 2 1 3 5 7 9 11 13 15 17 19 21 2 175 1 1 1 75 1 3 5 7 9 11 13 15 17 19 21 28 14 12 1 8 6 4 2 Pt 1 Pt 3 Pt 5 1 1 3 5 7 9 11 13 2 6 Pt 6 Pt 8 Pt 1 2 4 1 1 3 5 7 9 11 13 15 17 19 21 28 2 1 1 1 3 5 7 9 11 13 15 17 19 21 28 2 1 3 5 7 9 11 13 15 17 19 21 28 6 4 2 Pt 11 2 Pt 12 4 Pt 13 2 3 1 3 5 7 9 11 13 15 17 19 21 28 1 1 1 3 5 7 9 11 13 15 17 19 21 28 2 1 1 3 5 7 9 11 13 15 17 19 21 28 4 Pt 14 Sepsis 3 Pt 15 2 Pt 16 3 2 1 1 3 5 7 9 11 13 15 17 19 21 28 2 1 1 3 5 7 9 11 13 15 17 19 21 28 1 1 1 3 5 7 9 11 13 15 17 19 21 28 Nature Medicine: doi:1.138/nm.4441

Supplemental Figure 3: Serial measurements of CD22 site density on leukemic blasts in the presence of CD22 immune pressure demonstrate variability over time. Nature Medicine: doi:1.138/nm.4441

Supplemental Figure 4. Whole Exome and RNAseq profiling of CD22 in Primary Patient Sample recurring in the presence of CD22 CAR Immune Pressure. (a) Genome-wide copy number profiling of Patient #3 demonstrates no gains or losses with maintenance of the ploidy status before and after therapy. Neither mutations or focal copy number changes were observed in the CD22 gene locus for patient #3. (b) CD22 transcript levels were noted to slightly increase after CD22 CAR treatment. Nature Medicine: doi:1.138/nm.4441

Supplemental Figure 5. In vitro killing of CD19+/CD22+ ALL and single antigen expressing targets by CD19 CAR, CD22 CAR and a CD19xCD22 bispecific CAR. Killing of parental Nalm6 (CD19+/CD22+) and Nalm6 with crispr/cas9 mediated deletion of CD19 or CD22 (CD19Neg and CD22Neg) by CD19 CAR, CD22CAR and the bispecific CD19xCD22 CAR at various effector to target ratios. Killing is measured as loss of GFP positive tumor cells over time. Nature Medicine: doi:1.138/nm.4441

Supplemental Figure 6. Sequence of CD19xCD22 bispecific CAR. 5 ctagcgccaccatgctgctgctcgtgacaagcctgctgctgtgcgagctgccccaccctgcctttctgctgatccccgacatcca gatgacccagaccaccagcagcctgagcgccagcctgggcgatagagtgaccatcagctgcagagccagccaggacatcagcaa gtacctgaactggtatcagcagaaacccgacggcaccgtgaagctgctgatctaccacaccagcagactgcacagcggcgtgccca gcagattttctggcagcggctccggcaccgactacagcctgaccatctccaacctggaacaggaagatatcgctacctacttctgtca gcaaggcaacaccctgccctacaccttcggcggaggcaccaagctggaaatcacaggcggcggaggatcccaggtgcagctgcag cagtctggacccggcctcgtgaagcctagccagaccctgtctctgacctgcgccatcagcggcgatagcgtgtccagcaatagcgcc gcctggaactggatccggcagagcccttctagaggcctggaatggctgggccggacctactaccggtccaagtggtacaacgacta cgccgtgtccgtgaagtcccggatcaccatcaaccccgacaccagcaagaaccagttctccctgcagctgaacagcgtgacccccg aggataccgccgtgtactactgcgccagagaagtgaccggcgacctggaagatgccttcgacatctggggccagggcacaatggtc accgtgtctagcggcagcacaagcggctctggcaagcctggatctggcgagggctctaccaagggcgatattcagatgacacagag cccctccagcctgtccgcctctgtgggagacagagtgacaatcacctgtcgggcctcccagaccatctggtcctatctgaattggtatc agcagcggcctggcaaggcccccaacctgctgatctatgccgccagctctctgcagtccggcgtgccatctagattcagcggcagag gcagcggcaccgatttcaccctgacaattagcagtctgcaggccgaggacttcgccacctactattgccagcagagctacagcatcc cccagaccttcggccagggaacaaaactggaaatcaaagggggaggcggcagcgaagtgaaactgcaggaatctggccctggcc tggtggccccaagccagtctctgagcgtgacctgtaccgtgtctggcgtgtccctgcccgattacggcgtgtcctggatcagacagcc ccccagaaagggactggaatggctgggagtgatctggggcagcgagacaacctactacaacagcgccctgaagtccaggctgacc atcatcaaggacaactccaagagccaggtgttcctgaagatgaattccctgcagaccgacgacaccgccatctattactgtgccaag cactactactacggcggcagctacgccatggactactggggacagggaacctccgtgaccgtgtcctcttccggaaccacgacgcc agcgccgcgaccaccaacaccggcgcccaccatcgcgtcgcagcccctgtccctgcgcccagaggcgtgccggccagcggcgggg ggcgcagtgcacacgagggggctggacttcgcctgtgatatctacatctgggcgcccttggccgggacttgtggggtccttctcctgt cactggttatcaccctttactgcaaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactac tcaagaggaagatggctgtagctgccgatttccagaagaagaagaaggaggatgtgaactgagagtgaagttcagcaggagcgc agacgcccccgcgtacaagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggac aagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaa agataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccaggg tctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctcgctaagtc 3 Nature Medicine: doi:1.138/nm.4441